What Human Clinical Trials on NR Actually Show

Nicotinamide riboside has been studied in human clinical trials longer than NMN, and its evidence base is correspondingly larger. ChromaDex’s investment in Niagen — the patented NR ingredient — funded a systematic program of human clinical research that produced more and earlier pharmacokinetic and efficacy data than NMN accumulated in its first years on the market. That head start in human research is one of NR’s genuine advantages as a supplement choice, and understanding what those trials actually found — not what the marketing says they found — is the purpose of this article.

The picture that emerges from the NR human trial literature is similar in structure to NMN’s, but with some important distinctions: consistent and reliable NAD+ elevation, a solid safety record across a wide range of doses and populations, and a mixed picture on downstream functional effects that reflects the complexity of translating NAD+ biology into measurable human outcomes.

Pharmacokinetics and Safety: The Foundation

The foundational human pharmacokinetics data for NR comes from Trammell et al. (2016), published in Nature Communications — one of the most-cited papers in the NAD+ precursor literature. This randomized crossover trial gave healthy adults a single oral dose of 100 mg, 300 mg, or 1,000 mg of NR chloride (Niagen) and measured blood NAD+ metabolites over 24 hours.

Key findings:

• All three doses produced dose-dependent, statistically significant increases in blood NAD+ and related metabolites, including NMN, NAAD, and ADPR
• The increases were rapid — appearing within hours of ingestion — and sustained over the measurement period
• NAAD (nicotinic acid adenine dinucleotide) emerged as a particularly sensitive biomarker of NR supplementation, showing large, reliable increases that made it useful for confirming supplement compliance in subsequent trials
• No adverse effects were observed at any dose

The NAAD finding is methodologically important beyond this specific trial: it gave NR researchers a highly sensitive biomarker to confirm that participants were actually taking their supplement and responding to it — a tool that has improved the interpretability of subsequent NR trials.

Safety across a broader population was confirmed in Dellinger et al. (2017) in NPJ Aging, which administered NR at 250 mg twice daily for eight weeks in healthy older adults and found no adverse effects alongside significant NAD+ elevation. The safety profile of NR across the dose ranges studied in humans — from 100 mg to 2,000 mg per day — is well-established and reassuring.

NAD+ Elevation: Consistent Across Populations and Doses

The most reliable finding in the NR human trial literature is the one most relevant to the fundamental mechanism: NR consistently and substantially raises blood NAD+ levels in humans across a wide range of populations, doses, and trial designs. This is not in dispute and has been replicated in multiple independent trials.

Martens et al. (2018) in Nature Communications randomized 24 healthy older adults to NR at 500 mg twice daily (1,000 mg/day) or placebo for six weeks in a crossover design. Blood NAD+ levels in the NR group increased by approximately 60% relative to placebo — a large and consistent effect. Muscle NAD+ also increased significantly, confirming that the blood NAD+ elevation reflects genuine tissue uptake rather than merely circulating precursor accumulation.

The muscle NAD+ finding in Martens et al. is particularly important for interpreting NR’s relevance to physical function and aging: it demonstrates that orally administered NR reaches and elevates NAD+ in a functionally important tissue, not just in blood. This closes a key gap in the mechanistic chain from supplementation to cellular effect.

Cardiovascular Effects: The Most Developed Human Application

Cardiovascular aging — specifically arterial stiffness and blood pressure — has been the most extensively studied functional application of NR in humans, and here the evidence is among the most clinically meaningful in the NAD+ precursor literature.

Martens et al. (2018) — the same trial that confirmed muscle NAD+ elevation — also measured aortic stiffness and systolic blood pressure. In the subset of participants with elevated systolic blood pressure at baseline, NR at 1,000 mg/day for six weeks produced significant reductions in both aortic stiffness and systolic blood pressure. Participants with normal blood pressure at baseline showed no significant change — a pattern consistent with an intervention that corrects dysfunction rather than producing pharmacological lowering irrespective of baseline status.

Increasing aortic stiffness is one of the most important cardiovascular changes associated with aging, independently predicting cardiovascular events, cognitive decline, and kidney function decline. An intervention that reduces aortic stiffness in humans with elevated baseline values is addressing a clinically meaningful endpoint, not just a biomarker.

Follow-up work by the same group and others has explored the mechanisms underlying this cardiovascular effect. NAD+-dependent SIRT1 activation appears to reduce the expression of inflammatory and profibrotic genes in vascular smooth muscle — a mechanism consistent with reducing arterial stiffness over time. The broader context for NAD+ and cardiovascular health is covered in the article on NAD+ and cardiovascular health.

Metabolic Effects: Mixed Results Across Populations

NR’s metabolic effects — insulin sensitivity, glucose metabolism, lipid handling — have been studied in multiple populations with variable results that reflect an important underlying pattern: effects are more pronounced in metabolically compromised individuals than in metabolically healthy ones.

Remie et al. (2020) in Cell Metabolism conducted a rigorous 12-week randomized controlled trial of NR at 1,000 mg/day in overweight, middle-aged adults. The trial found significant increases in skeletal muscle NAD+ and increases in muscle mitochondrial protein content — suggesting genuine mitochondrial effects in muscle tissue. However, the trial found no significant improvements in insulin sensitivity, hepatic lipid content, or other metabolic endpoints in this population.

This is a sobering finding from a high-quality trial that deserves honest engagement. A metabolically significant increase in muscle mitochondrial protein without a corresponding improvement in insulin sensitivity suggests that either the timeframe was insufficient for downstream functional effects to emerge, or that NAD+ replenishment alone does not translate to metabolic improvement in overweight but not severely insulin-resistant adults within 12 weeks.

Dollerup et al. (2018) in Nature Communications similarly found no improvement in insulin sensitivity in obese men with prediabetes receiving 1,000 mg/day NR for 12 weeks, despite significant NAD+ elevation. This directly contrasts with the NMN insulin sensitivity finding from Yoshino et al. — a difference that may reflect the populations studied (postmenopausal women with prediabetes vs. obese men with prediabetes), the precursor used (NMN vs. NR), or genuine mechanistic differences that have not been resolved.

The metabolic picture for NR in humans is therefore more complicated than simple NAD+ elevation might imply: robust NAD+ and mitochondrial effects, less consistent translation to functional metabolic improvement in the populations studied to date.

Physical Performance and Muscle Function

The relationship between NR supplementation and physical performance has been examined in several trials, with results that are suggestive but not yet definitive.

Crisol-Martínez et al. (2021) found improvements in cardiorespiratory fitness measures in older adults receiving NR at 500 mg/day alongside a 12-week exercise program. The challenge of interpreting exercise co-intervention trials — discussed also in the context of NMN — applies here: separating the NR effect from the exercise effect requires careful design, and results from trials with both components cannot be cleanly attributed to supplementation alone.

Elhassan et al. (2019) in Cell Reports Medicine studied NR at 1,000 mg/day in healthy older men and found increases in skeletal muscle NAD+ alongside improvements in mitochondrial function markers in muscle biopsies. These mechanistic findings support the hypothesis that NR improves muscle mitochondrial health, but without a functional performance primary endpoint in this trial, translation to meaningful physical outcomes remains an inference rather than a direct measurement.

Neurological and Cognitive Applications: Early Signals

NR’s neurological applications have attracted significant research interest, driven by the well-characterized role of NAD+ in neuronal energy metabolism, DNA repair, and the function of SIRT1 and PARP1 in neurons. Several conditions involving neurological dysfunction have been studied.

Hou et al. (2021) conducted a small trial of NR in patients with mild cognitive impairment and found significant improvements in cognitive test scores alongside changes in cerebrospinal fluid biomarkers associated with Alzheimer’s pathology. This is an early-phase signal in a disease context rather than healthy aging, and the sample was small, but it is among the more intriguing human NR findings and is driving follow-on research in larger Alzheimer’s populations.

A trial by Brakedal et al. (2022) in Cell Metabolism examined NR in Parkinson’s disease patients, finding significant brain NAD+ elevation measured by MRI spectroscopy and improvements in mitochondrial function markers. This confirmed that orally administered NR can raise NAD+ in the human brain — a meaningful finding for any neurological application.

In healthy adults, the cognitive evidence is thinner, paralleling the NMN situation. The mechanistic case for NAD+ supporting brain health is strong; translating it to measurable cognitive improvements in cognitively normal adults has not been accomplished in well-powered human trials. The article on NAD+ and cognitive decline covers this evidence landscape in full.

NR in Specific Conditions and Disease Populations

Beyond healthy aging, NR has been studied in a range of disease contexts that illustrate both its potential and the complexity of translating NAD+ biology to clinical outcomes.

In heart failure, Diguet et al. (2018) in Circulation showed NR prevented cardiac dysfunction in a mouse model, and small human pilot data has suggested safety and NAD+ elevation in heart failure patients. Larger trials in cardiac populations are ongoing.

In non-alcoholic fatty liver disease (NAFLD), NR has shown reductions in hepatic lipid content in some trials, consistent with NAD+’s role in hepatic fat metabolism. These findings are in disease-context populations and cannot be generalized to healthy adults.

The disease-context findings are valuable for understanding NR’s mechanisms and for identifying specific therapeutic applications, but they inform rather than directly establish the value of NR supplementation in healthy adults seeking longevity benefits.

What the NR Trials Do Not Establish

As with NMN, stating what the evidence does not support matters as much as what it does:

Universal metabolic improvement: The Dollerup and Remie trials — two of the most rigorous NR metabolic trials — did not find insulin sensitivity improvements in their populations despite significant NAD+ elevation. The Martens cardiovascular findings were specific to participants with elevated baseline blood pressure. Effects are not universal and do not reliably occur in metabolically normal adults.

Cognitive enhancement in healthy adults: No well-powered trial has demonstrated NR improving cognition in cognitively normal people. The Hou and Brakedal trials were in disease populations.

Lifespan extension: No human trial data exists on this question, and none is forthcoming in any practical timeframe given the trial design requirements.

Superiority over NMN: NR’s larger evidence base reflects its earlier commercial development and ChromaDex’s investment in clinical research, not a proven performance advantage. No head-to-head trial has established that NR produces greater NAD+ elevation or better health outcomes than equivalent doses of NMN. The comparison is covered in the article on NMN vs. NR.

The Overall Picture

NR’s human clinical evidence base is the most developed of any NAD+ precursor — larger than NMN’s, more diverse in population coverage, and extending into neurological disease contexts that NMN trials have not yet reached. The core findings are solid: NR reliably raises blood and tissue NAD+ levels, it is safe across the dose range studied, and it produces cardiovascular effects in people with elevated arterial stiffness and blood pressure that are clinically meaningful.

Where the evidence is more equivocal — metabolic effects in overweight but not severely metabolically impaired adults, physical performance benefits, cognitive outcomes in healthy people — the picture is consistent with a theme seen throughout longevity supplement research: effects are more reliably demonstrated where there is more dysfunction to correct. That is not a dismissal of NR’s potential in preventive contexts; it is an accurate characterization of what current evidence supports.

Frequently Asked Questions

Does the larger NR evidence base mean NR is a better supplement than NMN?

Not necessarily. A larger evidence base reflects earlier commercial investment in clinical research rather than proven efficacy superiority. NMN has been catching up in human trial volume over the past three years, and its trials have produced some of the most functionally meaningful findings in the NAD+ precursor literature — particularly the Yoshino insulin sensitivity trial and the Yi physical performance trial. The evidence bases are different in character rather than clearly ordered by quality.

Why did some rigorous NR trials find no metabolic improvement?

The Dollerup and Remie trials found robust NAD+ elevation without corresponding insulin sensitivity improvements. Several explanations are plausible: the timeframe may have been insufficient for metabolic adaptations to emerge from improved mitochondrial function; the populations studied may not have had the degree of metabolic dysfunction where NAD+ repletion produces measurable change; or NAD+ elevation may not be sufficient alone to improve insulin sensitivity without complementary dietary or exercise interventions. The honest answer is that the mechanism by which NAD+ elevation should translate to improved insulin sensitivity has more complexity than simple supplement-to-outcome linearity, and the human data reflects that complexity.

Is the brain NAD+ finding from the Parkinson’s trial relevant to healthy aging?

The confirmation that orally administered NR raises brain NAD+ in humans — measured directly by MRI spectroscopy — is relevant beyond the disease context in which it was demonstrated. It establishes that NR can cross the blood-brain barrier and elevate NAD+ in neural tissue, which is a prerequisite for any neurological benefit in healthy aging as well as disease. The therapeutic magnitude of brain NAD+ elevation in healthy adults is a separate question that has not been directly studied.

How does NR compare to niacin for raising NAD+ levels?

Niacin (nicotinic acid) is an established and highly effective NAD+ precursor that has been used clinically for decades, primarily for its lipid-modifying effects. It raises NAD+ through a different pathway than NR and at pharmacological doses is potent. The significant disadvantage of niacin is the well-known flushing reaction — cutaneous vasodilation causing skin redness and warmth — that occurs in most people and limits tolerability and compliance. NR raises NAD+ without activating the receptor responsible for flushing, making it far better tolerated. For longevity supplementation where sustained long-term use is the goal, NR’s tolerability advantage over niacin is practically significant even if niacin is comparably potent at raising NAD+.